Bisherige Erfahrungen mit Griseofulvin

Ohne Zusammenfassung     

Griseofulvin therapy of lichen planus

Thirty-one patients who had lichen planus treated with griseofulvin were randomly selected for review from a group of patients with lichen planus seen at the Mayo Clinic between January 1976 and June 1980; two patients were excluded because of lack of adequate follow-up. Of the 11 patients with only oral lesions, 6 showed a marked improvement or complete remission. Of the 18 patients with lichen planus involving one or more sites with or without oral lesions, 15 had cutaneous lesions. Three of the 15 had improvement of their cutaneous lesions; however, 1 of the 3 continued to develop new lesions, although old ones were improving. In patients with recalcitrant, symptomatic oral lichen planus, a trial of griseofulvin would seem justified. Success in patients with cutaneous lichen planus is less likely; however, griseofulvin may afford relief in selected patients. This study indicates that further prospective studies are needed to clarify the efficacy of griseofulvin in lichen planus.     

Beobachtungen bei der Mikrosporietherapic mit Griseofulvin

Ohne Zusammenfassung     

Griseofulvin in the treatment of herpes zoster

The authors applied griseofulvin in 46 patients (28 women and 18 men) aged from 21 to 82 years with various forms of zoster. The locations of lesions was different: concerned very often the face and the thorax, rarely the extremities and sometimes the lesions were generalized. The treatment was started in beginning stadium of disease. The total daily oral dose of Griseofulvin-Forte (Medexport/SU were 500 mg (taken in two doses with 2 tablets a 125 mg). A average time of therapy was 10 days. Subjective troubles, pain and burning regressed rapidly and the regression endured. In author's opinion treatment with griseofulvin is efficacious and secure. The time of therapy is very short. The above mentioned method can be recommended to wide, general use.